Peng Li is a Cardiology physician. ClinicalTrials.gov lists 9 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Mmc- Cardiology Associates
3201 Grand Concourse, Ste. 1j
Bronx, NY 10468
Telephone
718-933-2244Registry record last updated 8 Jul 2007.
Clinical trials
- Prediction Model for Postoperative Headache After Transsphenoidal Pituitary Surgery
Sponsor: Beijing Tiantan Hospital
- The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC
Sponsor: Qilu Hospital of Shandong University
- The Effects of Exercise Intervention on Skeletal Muscle and Other Organs in Aged Population and the Discovery of Associated Circulating Biomarkers
Sponsor: National Yang Ming Chiao Tung University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABIOMEDProgram year20251 payment
- BridgeBio Pharma, Inc.Program year20252 payments
- Abbott LaboratoriesProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.4%Beta blocker20.3%Metoprolol Succinate81%Carvedilol11%Metoprolol Tartrate3%Atenolol3%Nebivolol Hcl2%Part D<11 patientsAngiotensin receptor blocker (ARB)14.8%Losartan Potassium44%Losartan-Hydrochlorothiazide21%Valsartan18%Valsartan-Hydrochlorothiazide7%Irbesartan-Hydrochlorothiazide5%Irbesartan4%Telmisartan3%Part D<11 patients+ 18 more classes in this area
Blood & clotting
11.3%Factor Xa inhibitor9%Eliquis64%Xarelto36%Part D≥59 patientsP2Y12 inhibitor1.5%Clopidogrel100%Part D≥20 patients+ 1 more class in this area
Metabolism & gastrointestinal
5.2%SGLT2 inhibitor2.1%Jardiance51%Farxiga49%Part D≥16 patientsProton pump inhibitor1.3%Pantoprazole Sodium100%Part D≥18 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”